Micron’s stock could wield 40% upside — even though earnings may not be a driver
A Wolfe analyst doesn’t think next week’s earnings report will prove a “meaningful catalyst” for Micron shares. He’s more enthused about earnings power over the...
A Wolfe analyst doesn’t think next week’s earnings report will prove a “meaningful catalyst” for Micron shares. He’s more enthused about earnings power over the...
This analyst is recommending buying the bonds given the company’s huge free cash flow and minimal leverage.
The Federal Reserve may increase stress capital buffers at Truist Financial Corp. and KeyCorp and ease them for Goldman Sachs Group Inc., Citigroup Inc. and...
Investors poured money into technology funds at a record pace over the past week, as surging demand for artificial-intelligence winners like Nvidia helped the chip...
Eli Lilly said Friday that it has applied for U.S. regulatory approval to expand the use of its weight-loss drug Zepbound to include treatment of...
Donald Trump is embracing cryptocurrency in his bid for the White House, and the crypto industry is hugging back.
Some patients with obstructive sleep apnea and obesity who took the highest dose of Zepbound achieved "disease resolution," in the two trials.
Rising tensions in the Middle East following an Israeli military attack on Hezbollah targets in southern Lebanon are bound to raise concerns about crude supplies...
Aggregate retail-investor portfolios are beating market benchmarks like the S&P 500 this year and closely trailing the Nasdaq, according to data from Vanda Research.